Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration

In oncology, combinations of drugs are often used to improve treatment efficacy and/or reduce harmful side effects. Dual‐agent phase I clinical trials assess drug safety and aim to discover a maximum tolerated dose combination via dose‐escalation; cohorts of patients are given set doses of both drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheeler, Graham M., Sweeting, Michael J., Mander, Adrian P., Lee, Shing M., Cheung, Ying Kuen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Special Issue Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157785/
https://www.ncbi.nlm.nih.gov/pubmed/26891942
http://dx.doi.org/10.1002/sim.6912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157785/
https://www.ncbi.nlm.nih.gov/pubmed/26891942
http://dx.doi.org/10.1002/sim.6912

Ejemplares similares